A practical and direct comparison of intrinsic metabolic clearance of several non-CYP enzyme substrates in freshly isolated and cryopreserved hepatocytes

Drug Metabolism and Pharmacokinetics

Volumn 27, Issue 2, 2012, Pages 181-191

  Akabane, Takafumi ^a,b   Gerst, Nicolas ^a   Naritomi, Yoichi ^b   Masters, Jeffrey N ^a   Tamura, Kouichi ^a  

^a Astellas Research Institute of America LLC   (United States)

^b ASTELLAS PHARMA INC   (Japan)

Author keywords

Drug clearance; Drug discovery; Isolated hepatocytes; Metabolism

Indexed keywords

6 [2 AMINO 4 PHENYLPYRIMIDIN 5 YL] 2 ISOPROPYLPYRIDAZIN 3(2H) ONE; ALDEHYDE OXIDASE; ALDO KETO REDUCTASE; BENZYDAMINE; CARBONYL REDUCTASE; DICLOFENAC; DIMETHYLANILINE MONOOXYGENASE; DOLASETRON MESILATE; EZETIMIBE; FK 3453; GEMFIBROZIL; GLUCURONOSYLTRANSFERASE; GUANINE DERIVATIVE; KETANSERIN; METYRAPONE; MONOAMINEOXIDASE; NALOXONE; NALTREXONE; O6 BENZYGUANINE; OXIDOREDUCTASE; PHTHALAZINE; PHTHALAZINE DERIVATIVE; PYRIDAZINE DERIVATIVE; SUMATRIPTAN; UNCLASSIFIED DRUG; ZALEPLON;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL ISOLATION; COMPARATIVE STUDY; CONTROLLED STUDY; CRYOPRESERVATION; DRUG CLEARANCE; DRUG METABOLISM; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME SUBSTRATE COMPLEX; FEMALE; HUMAN; HUMAN CELL; INTRINSIC CLEARANCE VALUE; LIVER CELL; MALE; METABOLIC CLEARANCE RATE; PHARMACOLOGICAL PARAMETERS;

EID: 84860281804     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-11-RG-097     Document Type: Article

References (42)

1. De Buck, S. S., Sinha, V. K., Fenu, L. A., Nijsen, M. J., Mackie, C. E. and Gilissen, R. A.: Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab. Dispos., 35: 1766-1780 (2007).
2. Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H. and Sugiyama, Y.: Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm. Drug Dispos., 17: 273-310 (1996).
3. Naritomi, Y., Terashita, S., Kimura, S., Suzuki, A., Kagayama, A. and Sugiyama, Y.: Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab. Dispos., 29: 1316-1324 (2001).
4. Sinha, V. K., De Buck, S. S., Fenu, L. A., Smit, J. W., Nijsen, M., Gilissen, R. A., Van Peer, A., Lavrijsen, K. and Mackie, C. E.: Predicting oral clearance in humans: how close can we get with allometry? Clin. Pharmacokinet., 47: 35-45 (2008).
5. Wishart, D. S.: Improving early drug discovery through ADME modelling: an overview. Drugs R D., 8: 349-362 (2007).
6. Nassar, A. E., Kamel, A. M. and Clarimont, C.: Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability. Drug Discov. Today, 9: 1020-1028 (2004).
7. Thompson, T. N.: Optimization of metabolic stability as a goal of modern drug design. Med. Res. Rev., 21: 412-449 (2001).
8. Williams, J. A., Hyland, R., Jones, B. C., Smith, D. A., Hurst, S., Goosen, T. C., Peterkin, V., Koup, J. R. and Ball, S. E.: Drugdrug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab. Dispos., 32: 1201-1208 (2004).
9. Torres, R. A., Korzekwa, K. R., McMasters, D. R., Fandozzi, C. M. and Jones, J. P.: Use of density functional calculations to predict the regioselectivity of drugs and molecules metabolized by aldehyde oxidase. J. Med. Chem., 50: 4642-4647 (2007).
10. Rosemond, M. J. and Walsh, J. S.: Human carbonyl reduction pathways and a strategy for their study in vitro. Drug Metab. Rev., 36: 335-361 (2004).
11. Akabane, T., Tanaka, K., Irie, M., Terashita, S. and Teramura, T.: Case report of extensive metabolism by aldehyde oxidase in humans: Pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans. Xenobiotica, 41: 372-384 (2011).
12. Zientek, M., Jiang, Y., Youdim, K. and Obach, R. S.: In vitroin vivo correlation for intrinsic clearance for drugs metabolized by aldehyde oxidase. Drug Metab. Dispos., 38: 1322-1327 (2010).
13. Li, A. P.: Human hepatocytes: Isolation, cryopreservation and applications in drug development. Chem. Biol. Interact., 168: 16-29 (2007).
14. Li, A. P.: Evaluation of Drug Metabolism, Drug-Drug Interactions, and In Vitro Hepatotoxicity with Cryopreserved Human Hepatocytes. Methods Mol. Biol., 640: 281-294 (2010).
15. Soars, M. G., McGinnity, D. F., Grime, K. and Riley, R. J.: The pivotal role of hepatocytes in drug discovery. Chem. Biol. Interact., 168: 2-15 (2007).
16. Soars, M. G., Webborn, P. J. and Riley, R. J.: Impact of hepatic uptake transporters on pharmacokinetics and drug-drug interactions: use of assays and models for decision making in the pharmaceutical industry. Mol. Pharm., 6: 1662-1677 (2009).
17. Floby, E., Johansson, J., Hoogstraate, J., Hewitt, N. J., Hill, J. and Sohlenius-Sternbeck, A. K.: Comparison of intrinsic metabolic clearance in fresh and cryopreserved human hepatocytes. Xenobiotica, 39: 656-662 (2009).
18. McGinnity, D. F., Soars, M. G., Urbanowicz, R. A. and Riley, R. J.: Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab. Dispos., 32: 1247-1253 (2004).
19. Naritomi, Y., Terashita, S., Kagayama, A. and Sugiyama, Y.: Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab. Dispos., 31: 580-588 (2003).
20. Li, A. P., Lu, C., Brent, J. A., Pham, C., Fackett, A., Ruegg, C. E. and Silber, P. M.: Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem. Biol. Interact., 121: 17-35 (1999).
21. Combourieu, B., Besse, P., Sancelme, M., Maser, E. and Delort, A. M.: Evidence of metyrapone reduction by two Mycobacterium strains shown by 1H NMR. Biodegradation, 15: 125-132 (2004).
22. Chiarotto, J. A. and Wainer, I. W.: Determination of metyrapone and the enantiomers of its chiral metabolite metyrapol in human plasma and urine using coupled achiral-chiral liquid chromatography. J. Chromatogr. B, Biomed. Appl., 665: 147-154 (1995).
23. Dixon, C. M., Park, G. R. and Tarbit, M. H.: Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver. Biochem. Pharmacol., 47: 1253-1257 (1994).
24. Chao, P., Uss, A. S. and Cheng, K. C.: Use of intrinsic clearance for prediction of human hepatic clearance. Expert Opin. Drug Metab. Toxicol., 6: 189-198 (2010).
25. Shibata, Y., Takahashi, H., Chiba, M. and Ishii, Y.: Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method. Drug Metab. Dispos., 30: 892-896 (2002).
26. Swales, N. J. and Utesch, D.: Metabolic activity of fresh and cryopreserved dog hepatocyte suspensions. Xenobiotica, 28: 937-948 (1998).
27. Garattini, E. and Terao, M.: Increasing recognition of the importance of aldehyde oxidase in drug development and discovery. Drug Metab. Rev., 43: 374-386 (2011).
28. Garattini, E., Fratelli, M. and Terao, M.: Mammalian aldehyde oxidases: genetics, evolution and biochemistry. Cell. Mol. Life Sci., 65: 1019-1048 (2008).
29. Roy, S. K., Korzekwa, K. R., Gonzalez, F. J., Moschel, R. C. and Dolan, M. E.: Human liver oxidative metabolism of O6-benzylguanine. Biochem. Pharmacol., 50: 1385-1389 (1995).
30. Renwick, A. B., Mistry, H., Ball, S. E., Walters, D. G., Kao, J. and Lake, B. G.: Metabolism of Zaleplon by human hepatic microsomal cytochrome P450 isoforms. Xenobiotica, 28: 337-348 (1998).
31. Kitamura, S., Sugihara, K. and Ohta, S.: Drug-metabolizing ability of molybdenum hydroxlases. Drug Metab. Pharmacokinet., 21: 83-98 (2006).
32. Beedham, C., Bruce, S. E., Critchley, D. J. and Rance, D. J.: 1-substituted phthalazines as probes of the substrate-binding site of mammalian molybdenum hydroxylases. Biochem. Pharmacol., 39: 1213-1221 (1990).
33. Panoutsopoulos, G. I. and Beedham, C.: Enzymatic oxidation of phthalazine with guinea pig liver aldehyde oxidase and liver slices: inhibition by isovanillin. Acta Biochim. Pol., 51: 943-951 (2004).
34. Obach, R. S.: Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metab. Dispos., 32: 89-97 (2004).
35. Jouin, D., Blanchard, N., Alexandre, E., Delobel, F., David- Pierson, P., Lavé, T., Jaeck, D., Richert, L. and Coassolo, P.: Cryopreserved human hepatocytes in suspension are a convenient high throughput tool for the prediction of metabolic clearance. Eur. J. Pharm. Biopharm., 63: 347-355 (2006).
36. Kilford, P. J., Stringer, R., Sohal, B., Houston, J. B. and Galetin, A.: Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Drug Metab. Dispos., 37: 82-89 (2009).
37. Ritter, J. K.: Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics. Expert Opin. Drug Metab. Toxicol., 3: 93-107 (2007).
38. Dimmitt, D. C., Choo, Y. S., Martin, L. A., Arumugham, T., Hahne, W. F. and Weir, S. J.: Intravenous pharmacokinetics and absolute oral bioavailability of dolasetron in healthy volunteers:part 1. Biopharm. Drug Dispos., 20: 29-39 (1999).
39. Persson, B., Heykants, J. and Hedner, T.: Clinical pharmacokinetics of ketanserin. Clin. Pharmacokinet., 20: 263-279 (1991).
40. Wall, M. E., Brine, D. R. and Perez-Reyes, M.: Metabolism and disposition of naltrexone in man after oral and intravenous administration. Drug Metab. Dispos., 9: 369-375 (1981).
41. Beedham, C.: Molybdenum hydroxylases: biological distribution and substrate-inhibitor specificity. Prog. Med. Chem., 24: 85-127 (1987).
42. Fisher, M. B., Yoon, K., Vaughn, M. L., Strelevitz, T. J. and Foti, R. S.: Flavin-containing monooxygenase activity in hepatocytes and microsomes: in vitro characterization and in vivo scaling of benzydamine clearance. Drug Metab. Dispos., 30: 1087-1093 (2002).